DIASORIN LAUNCHES THE FIRST FULLY AUTOMATED CLIA ASSAYS FOR THE DETECTION OF CHLAMYDIA TRACHOMATIS ON ITS LIAISON PLATFORMS

June 28, 2013 - Saluggia (VC) - DiaSorin (FTSE MIB:DIA) launches on the market the Chlamydia Trachomatis IgG and IgA assays on the LIAISON analyzer family, available outside the US and Canada only, providing the first fully automated CLIA tests to be used in the determination of serological status of the Chlamydia Trachomatis infectious disease.

The new Chlamydia Trachomatis IgG and IgA assays on LIAISON platforms are intended to aid in the determination of antibodies to Chlamydia Trachomatis in human serum or plasma. These new DiaSorin tests represent both a more accurate, practical and faster solution than that on ELISA technology and a more economical solution for laboratories using more expensive technologies, such as molecular diagnostics.

Furthermore the new Chlamydia Trachomatis IgG and IgA assays satisfy customers’ needs like standardization among laboratories, easy to use, rapid and accurate identification of active infection, and assessment of past infection as possible cause of infertility and reactivation.

Chlamydia Trachomatis is one of the most common bacterial sexually transmitted infections in the world that can infect both men and women and cause serious, permanent damage to a woman's reproductive organs. When clinical manifestations are present, they include cervicitis, urethritis, endometritis or PID. Annual Chlamydia screening for young sexually active adults, particularly women, is already recommended in several European and American countries, where screening programs aim at reducing morbidity in individuals by early detection and treatment, and at decreasing the overall prevalence of infection in the population.

The number of diagnosed cases is increasing in many countries; in 2005 the World Health Organization (WHO) estimated that there were 101 million new cases of Chlamydia Trachomatis in adults between the age of 15 and 49 and this number is still increasing, with some big developed countries experiencing about 20 million new infections every year. As a consequence, Chlamydia Trachomatis is estimated to become one of the most spread-out infections in the world. For this reason a simple, rapid and economic automated solution is the key for effective diagnoses around the world.
Mr. Carlo Rosa, Chief Executive Officer of DiaSorin Group, said: “I am proud to announce the introduction of the DiaSorin Chlamydia Trachomatis assays which provide the first fully automated solution on CLIA technology in the diagnostic market, emphasizing DiaSorin’s positioning in the market more and more as the Diagnostic Specialist and further expanding the Company’s menu on LIAISON analyzer family which, today, is the broadest available on a single platform in the world”.

About DiaSorin
Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava
External Relations Director - Head of IR and Media
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Margherita Sacerdoti
Investor Relations Specialist
Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it